Bisphosphonates - the first line treatment for osteoporosis or osteopenia

Published On 2022-01-08 09:23 GMT   |   Update On 2022-01-08 09:23 GMT

As per WHO records 14.5% men suffer from osteoporosis and 18% in women and it is highly prevalent in menopausal women. Bisphosphonates are known to prevent bone loss in both osteoporosis and osteopenia. Bisphosphonates can be recommended as a first-line treatment for the prevention and treatment of osteoporosis and can decrease the risk of hip fracture among the general population, according to...

Login or Register to read the full article

 As per WHO records 14.5% men suffer from osteoporosis and 18% in women and it is highly prevalent in menopausal women. Bisphosphonates are known to prevent bone loss in both osteoporosis and osteopenia.  

Bisphosphonates can be recommended as a first-line treatment for the prevention and treatment of osteoporosis and can decrease the risk of hip fracture among the general population, according to a recent study published in the BMJ Journal.

This meta-analysis and systematic review investigated the efficacy of bisphosphonates on the incidence of hip fracture (IHF) in patients of different ages with osteoporosis or osteopenia. They reviewed trials reporting the effects of bisphosphonates on the incidence of hip fracture (IHF). The double blinded placebo trial found that there was biphosphonates reduced IHF in all age groups. The researchers pooled data using a random-effects meta-analysis with risk ratios (RRs) and reported 95% CIs. 

For more information check out the full story on the link below:

Bisphosphonates effective as first-line treatment for osteoporosis or ostopenia: Study 


Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News